acetylated peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | About 3.1 kDa | 28 residues, N-terminally acetylated |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in aqueous buffers |
| Storage temperature | 2 to 8 °C | Protect from light and moisture |
| Common synonyms | Thymalfasin; Tα1 | Same peptide sequence |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Lyophilized thymosin alpha-1 is generally stored at or below minus twenty degrees Celsius, protected from moisture and light. Short-term handling at ambient temperature is possible for dry powder, but reconstituted solutions degrade faster and are usually kept at two to eight degrees Celsius with a defined expiry of days rather than weeks. Repeated freeze-thaw cycles should be avoided because they promote aggregation and loss of potency. Exact limits depend on the formulation and should follow the supplier's documentation.
Identity and purity are normally assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and truncation products. Mass spectrometry confirms molecular mass and detects modifications such as deamidation or oxidation. Amino acid analysis and peptide mapping provide additional sequence-level confirmation. For research material, a certificate of analysis typically reports these results together with water content and counter-ion identity, since the lyophilized powder is often supplied as an acetate or trifluoroacetate salt.
=== Names === Enobosarm is the generic name of the drug and its International Nonproprietary Name (INN). Ostarine was a tentative brand name of the drug created by GTx, Inc. that did not end up being used for marketing purposes but continues to be used as a synonym for the drug. Enobosarm is also known by the pharmaceutical developmental code names S-22 (synthesis paper), GTx-024 (GTx, Inc.), MK-2866 (Merck), and VERU-024 (Veru, Inc.).
=== Ion implantation === Ion implantation has been used to create silver nanoparticles embedded in glass, polyurethane, silicone, polyethylene, and poly(methyl methacrylate). Particles are embedded in the substrate by means of bombardment at high accelerating voltages. At a fixed current density of the ion beam up to a certain value, the size of the embedded silver nanoparticles has been found to be monodisperse within the population, after which only an increase in the ion concentration is observed. A further increase in the ion beam dose has been found to reduce both the nanoparticle size and density in the target substrate, whereas an ion beam operating at a high accelerating voltage with a gradually increasing current density has been found to result in a gradual increase in the nanoparticle size. There are a few competing mechanisms which may result in the decrease in nanoparticle size; destruction of NPs upon collision, sputtering of the sample surface, particle fusion upon heating and dissociation. The formation of embedded nanoparticles is complex, and all of the controlling parameters and factors have not yet been investigated. Computer simulation is still difficult as it involves processes of diffusion and clustering, however it can be broken down into a few different sub-processes such as implantation, diffusion, and growth. Upon implantation, silver ions will reach different depths within the substrate which approaches a Gaussian distribution with the mean centered at X depth.
Andy Street, the Mayor of the West Midlands, announces that he and his Manchester counterpart, Andy Burnham, are to meet Mark Harper, the Secretary of State for Transport, to discuss proposals for a privately funded alternative to the abandoned Manchester leg of HS2. The UK is to lend several pieces of the Ghana crown jewels back to Ghana 150 years after looting them from the court of the Asante king. 25 January The UK government announces fresh plans to ban the sale of zombie knives, with legislation taking effect from the autumn. Lloyds Banking Group announces plans to cut around 1,600 positions from its branch staff in a reorganisation that it says is because more customers are banking online. 26 January Buckingham Palace confirms that King Charles III has been admitted to hospital for treatment for an enlarged prostate. Jürgen Klopp, currently the longest-serving manager in the Premier League, announces he is departing as manager of Liverpool F.C. after the conclusion of the 2023–24 season, and taking a break from football management. 27 January The UK government suspends funding for the UN agency for Palestinian refugees, UNRWA, after the organisation sacked several officials reported to have been involved in the 7 October attacks on Israel. Kemi Badenoch, the business secretary, asks Henry Staunton to step down as chair of Post Office Limited after 13 months in the role, as the government moves to strengthen governance at the Post Office in the wake of the long-running Horizon IT scandal.
Sources: en.wikipedia.org
== Intermediate == It is an intermediate in the catabolism of aromatic amino acids such as phenylalanine and tyrosine. 4-Hydroxyphenylpyruvate (produced by transamination of tyrosine) is acted upon by the enzyme 4-hydroxyphenylpyruvate dioxygenase to yield homogentisate. If active and present, the enzyme homogentisate 1,2-dioxygenase further degrades homogentisic acid to yield 4-maleylacetoacetic acid.
1993/1223) Value Added Tax (General) (Amendment) (No. 4) Regulations 1993 (S.I. 1993/1224) Bromley and Greenwich (London Borough Boundaries) Order 1993 (S.I. 1993/1225) Medicines (Veterinary Drugs) (Renewal Applications for Licences and Animal Test Certificates) Regulations 1993 (S.I. 1993/1227) Beer Regulations 1993 (S.I. 1993/1228) Financial Services (Designated Countries and Territories) (Overseas Insurance Companies) Order 1993 (S.I. 1993/1237) Scottish Hospital Endowments Research Trust (Amendment) Regulations 1993 (S.I. 1993/1238) National Savings Bank (Investment Deposits) (Limits) (Amendment) Order 1993 (S.I. 1993/1239) Soft Drinks (Amendment) Regulations 1993 (S.I. 1993/1240) South West Regional Flood Defence Committee Order 1993 (S.I. 1993/1241) Social Security (Widow's Benefit and Retirement Pensions) Amendment Regulations 1993 (S.I. 1993/1242) Child Abduction and Custody (Parties to Conventions) (Amendment) Order 1993 (S.I. 1993/1243) Iraq (United Nations) (Sequestration of Assets) Order 1993 (S.I. 1993/1244) Iraq (United Nations) (Sequestration of Assets) (Dependent Territories) Order 1993 (S.I. 1993/1245) Treaty on Open Skies (Privileges and Immunities) Order 1993 (S.I. 1993/1246) Treaty on Open Skies (Privileges and Immunities) (Overseas Territories) Order 1993 (S.I. 1993/1247) Turks and Caicos Islands Constitution (Amendment) Order 1993 (S.I. 1993/1248) Income-related Benefits Schemes and Social Security (Recoupment) Amendment Regulations 1993 (S.I. 1993/1249) Access to Health Records (Northern Ireland) Order 1993 (S.I.
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis). It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection and is known by patients as "fire in the veins". Melarsoprol has a high number of side effects. Common side effects include brain dysfunction, numbness, rashes, and kidney and liver problems. About 1–5% of people die during treatment, although this is tolerated due to sleeping sickness itself having a practically 100% mortality rate when untreated. In those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cell breakdown may occur. It has not been studied in pregnancy. While its mechanism of action is not fully understood, its covalent binding to trypanothione to form the toxic Mel T complex is thought to play a large role. Melarsoprol has been used medically since 1949. It is on the World Health Organization's List of Essential Medicines. In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization. It is not commercially available in Canada or the United States. In the United States, it may be obtained from the Centers for Disease Control and Prevention, while in Canada it is available from Health Canada.
Sources: en.wikipedia.org
It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.
The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.
No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.
Reconstituted solutions are typically kept refrigerated at two to eight degrees Celsius when used within a short window, or frozen in aliquots for longer periods. Repeated freeze-thaw cycles are avoided because they can reduce recovery of intact peptide.